REG - Avacta Group PLC - Annual General Meeting and Shareholder Event

AvactaAnnouncement

28/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230628:nRSb1053Ea&default-theme=true

RNS Number : 1053E  Avacta Group PLC  28 June 2023

 

 

28 June 2023

 

Avacta Group plc

 

("Avacta" or the "Company" and, together with its subsidiary undertakings, the
"Group")

 

Annual General Meeting and Shareholder Event

 

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative,
targeted oncology drugs and powerful diagnostics, is today holding its Annual
General Meeting ("AGM") of shareholders and, immediately following the AGM,
will hold a shareholder event comprising a business review and presentations
from the senior management teams of the Therapeutics and Diagnostics Divisions
with Q&A.

 

Avacta Chief Executive, Alastair Smith, will present a business review which
will outline the commercial and corporate strategy of the Group and its
divisions. The Business Update (11:00-12:00 BST) will be simultaneously
streamed live on the Investor Meet Company ("IMC") platform. Investors who
already follow Avacta on IMC will automatically be invited to join the live
stream. Investors who do not have an IMC account can sign up for free at
https://www.investormeetcompany.com/avacta-group-plc/register-investor
(https://www.investormeetcompany.com/avacta-group-plc/register-investor)  and
then click "Add to meet" on the Avacta page in order to receive an invitation.

 

A buffet lunch will be accompanied by poster presentations covering AVA6000,
AVA3996, Affimer(®) Therapeutics and the Launch Diagnostics business will
also be present at a booth. This will provide investors with the opportunity
to meet the senior management teams.

 

After lunch, the Company will discuss the AVA6000 Phase 1a clinical data that
was recently presented at the Company's Science Day and will present the
Diagnostics Division strategy.

 

Following closing comments and a final Q&A session, the event will end at
14:00 BST.

 

All presentation materials, including slide decks and posters, are now
available on the Company's website at
https://avacta.com/investors/investor-resources/
(https://avacta.com/investors/investor-resources/) .

 

-Ends-

 

For further information from Avacta Group plc, please contact:

 

 Avacta Group plc                                                                Tel: +44 (0) 1904 21 7070

 Alastair Smith, Chief Executive Officer                                         www.avacta.com (http://www.avacta.com)

 Tony Gardiner, Chief Financial Officer

 Michael Vinegrad, Group Communications Director

 Stifel Nicolaus Europe Limited (Nomad and Broker)                               Tel: +44 (0) 207 710 7600

 Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / Dhiren Suares   www.stifel.com (http://www.stifel.com/)
 / William Palmer-Brown

 FTI Consulting (Financial Media and IR)                                         Tel: +44(0) 203 727 1000

 Simon Conway / Alex Shaw                                                        Avacta.LS@fticonsulting.com (mailto:Avacta.LS@fticonsulting.com)

 Zyme Communications (Trade and Regional Media)                                  Tel: +44 (0)7891 477 378

 Lily Jeffery                                                                    lily.jeffery@zymecommunications.com

                                                                               (mailto:katie.odgaard@zymecommunications.com)

 

About Avacta Group plc - www.avacta.com (http://www.avacta.com)

 

Avacta Group plc is a life sciences company working to improve people's health
and well-being through innovative oncology drugs and powerful diagnostics.
Operating through two divisions, Diagnostics and Therapeutics, the Group's
mission is to provide professionals and consumers with solutions that improve
healthcare, fitness and well-being.

 

Avacta's Therapeutics Division, a clinical stage oncology drug innovator, is
building a wholly owned pipeline of novel Affimer(®) immunotherapies and
pre|CISION™ tumour targeted chemotherapies. This approach is designed to
address the lack of a durable response to current cancer immunotherapies
experienced by most patients and reduce the severe systemic toxicities caused
by chemotherapies. There are five programmes in the pipeline as well as
several global research collaborations and licensing partnerships. Avacta's
lead programme, AVA6000, is a pre|CISION™ tumour-targeted form of the
established chemotherapy doxorubicin. AVA6000 is in Phase I clinical trials in
patients with locally advanced or metastatic selected solid tumours.

 

The Affimer(®) platform is an alternative to antibodies that has been
designed to address many of the drawbacks of antibodies which, despite their
shortcomings, currently dominate the immuno-diagnostics and
immuno-therapeutics markets.

 

The pre|CISION™ tumour targeting platform can be used to modify a
chemotherapy in order to selectively release the active drug in tumour tissue
thereby reducing the systemic exposure that causes damage to healthy tissues.
pre|CISION™ modified chemotherapies are designed to reduce the side effects
and improve the overall safety and therapeutic potential of these powerful
anti-cancer treatments.

 

Avacta's Diagnostics Division develops and supplies a broad range of in-vitro
diagnostic (IVD) solutions. The Division is growing rapidly through an M&A
strategy to deliver a global scale IVD business providing market leading
solutions for healthcare professionals and consumers to inform treatment and
monitor health and well-being. In October 2022, Avacta acquired Launch
Diagnostics which serves the hospital pathology laboratory market in the UK
and Europe. In May 2023, Avacta acquired Coris Bioconcept a Belgium based
lateral flow test developer and manufacturer adding a broad range of marketed
professional-use rapid tests into the Diagnostics Division. Avacta
Diagnostic's research and development centre in Wetherby, UK uses its
proprietary Affimer(®) platform to differentiate immunodiagnostic products to
provide marketing leading performance.

 

To register for news alerts by email go to
www.avacta.com/investor-news-email-alerts
(http://www.avacta.com/investor-news-email-alerts)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFRMFTMTBTBPJ